ClinicalTrials.gg
RecruitingNCT06865235Updated Mar 7, 2025

Efficacy and Safety of Gonioscopy Assisted Transluminal Trabeculotomy in Patients with Primary Open-angle Glaucoma and Cataract.

An interventional study of 360º goniotomy assisted transluminal trabeculotomy and Phacoemulsification in Open Angle Glaucoma (OAG), sponsored by Faculdade de Ciências Médicas de Minas Gerais. Recruiting at 1 site in Brazil. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Faculdade de Ciências Médicas de Minas Gerais · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled May 2024, registered Feb 2025).
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Glaucoma, Open-Angle with a site in Brazil — 1 open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Brazil.

Planned enrollment
7th of 18
90 · median 55
Started
2024
the only one that year
No phase
5 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Faculdade de Ciências Médicas de Minas Gerais

Among the 18 studies in Glaucoma, Open-Angle with a site in Brazil, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 5 with no phase, and was the 18th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 18 studies in Glaucoma, Open-Angle with a site in Brazil is open now.

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glaucoma, Open-Angle with a site in Brazil, or all of them as a file.
02

Study summary

Prospective, randomized, , double-blind, clinical trial, comparing the variation of intraocular pressure (IOP) of patients with mild or moderate primary open-angle glaucoma (OAG) and cataract divided into three groups. All study participants should be treated for the pathology with one or more hypotensive medications or, regardless of the number of drugs, when IOP is greater than 20 mmHg and less than 26 mmHg. The two-year follow-up should also compare the reduction in the number of medications used, reoperation rate, adverse effects, visual acuity, endothelial loss, induction of astigmatism, variation in IOP according to axial diameter of the eye, anterior chamber and age, in addition to the existence of change in the quality of life of patients in the postoperative period

03

Conditions studied

  • Open Angle Glaucoma (OAG)

Keywords

  • Open angle glaucoma
  • Cataract
  • OAG
  • Goniotomy assisted transluminal trabeculotomy
  • GATT
  • trabeculotomy
  • Goniotomy
  • hemi-gatt
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 40 years or older,
  • Previously included in the glaucoma departments of the participating institutions,
  • Indication for cataract surgery, diagnosed by clinical examination with visual acuity (VA) equal to or worse than 20/40,
  • Primary Open Angle Glaucoma (POAG), determined by the presence of typical visual field (VF) defects and/or by the aspect of the optic nerve observed at fundoscopy or retinography (increased vertical optical excavation with thinning of the neural rhyme, asymmetry of the cup/disc ratio greater than 0.2, localized loss ("notch") or defect in the retinal nerve fiber layer ("Hoyt")).
  • APIC classification with amplitude greater/equal to 2 and pigmentation less than 4 on gonioscopy.
  • Intraocular pressure (IOP) less than or equal to 25 mmHg before washout of hypotensive eye drops.
  • IOP between 22 and 30 mmHg after washout of hypotensive eye drops or with a history of IOP greater than or equal to 21 mmHg in more than one previous care described in the medical record.

Exclusion criteria

Exclusion Criteria:

Patients who have any of the following situations:

  • Severe glaucoma, determined according to the Hoddap-Parrish-Anderson criteria;
  • Axial diameter greater than 26 mm or less than 21.00 mm;
  • Endothelial count less than 1500 cc;
  • Pachymetry less than 480 or greater than 600 microns;
  • Patients undergoing some type of intraocular surgery or laser procedure in the preoperative period and/or after these procedures in the postoperative period;
  • Those who present some important per-operative complication during the study.
  • With high risk of progression, the so-called rapid progressors, who are patients with high IOPs even with the use of many medications, regardless of the severity of the nerve injury.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Patients undergoing cataract surgery associated with GATT by 360º

    Procedure: 360º goniotomy assisted transluminal trabeculotomy · Procedure: Phacoemulsification

  • Experimental
    Patients undergoing cataract surgery associated with GATT by 180º

    Procedure: Phacoemulsification · Procedure: 180º gonioscopy assisted transluminal trabeculotomy

  • Other
    Patients undergoing only cataract surgery

    Control Group

    Procedure: Phacoemulsification

Interventions

  • Procedure360º goniotomy assisted transluminal trabeculotomy

    Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.

  • ProcedurePhacoemulsification

    Cataract Surgery

  • Procedure180º gonioscopy assisted transluminal trabeculotomy

    Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.

    Also known as: 180º GATT, Hemi - GATT

06

What researchers measure

Primary outcomes

  1. Change in intraocular pressure (IOP) after surgery.

    To evaluate the change in intraocular pressure (IOP) after surgery, in patients with mild to moderate GPAA, undergoing phacoemulsification associated with gonioscopy assisted transluminal trabeculotomy by 180º (GATT 180º) or 360º (GATT 360º), and compare the results between the groups mentioned and with similar controls, who operated only on cataracts, in a period of up to two years.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  2. Change in the number of glaucoma medications after surgery.

    To evaluate the change in the number of glaucoma medications applied after surgery, in patients with mild to moderate GPAA, undergoing phacoemulsification associated with gonioscopy assisted transluminal trabeculotomy by 180º (GATT 180º) or 360º (GATT 360º), and compare the results between the groups mentioned and with similar controls, who operated only on cataracts, in a period of up to two years.

    Time frame: From glaucoma medications washout to 2 years after the surgery

Secondary outcomes

  1. Prognostic factors of the surgeries.

    Evaluate the association of IOP variation with axial eye length (AXL) in the groups.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  2. Prognostic factors of the surgeries.

    Evaluate the association of IOP variation with preoperative anterior chamber amplitude (ACD) in the groups.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  3. Prognostic factors of the surgeries.

    Evaluate the association of IOP variation with age in the groups

    Time frame: From glaucoma medications washout to 2 years after the surgery

  4. Survival Analysis

    Evaluate and compare the need for new glaucoma surgeries between the groups.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  5. Secundary changes in the eye after the surgeries

    Evaluate the visual acuity after the surgeries and compare between them.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  6. Secundary changes in the eye after the surgeries

    Evaluate and compare the adverse events after the surgeries.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  7. Secundary changes in the eye after the surgeries

    Evaluate the decrease in corneal endothelial cell count between the groups.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  8. Prognostic factors, and secundary changes in the eye after the surgeries

    Evaluate and compare the change in quality of life in and between the groups.

    Time frame: From glaucoma medications washout to 2 years after the surgery

  9. Secundary changes in the eye after the surgeries

    Evaluate the induction of astigmatism between the groups

    Time frame: From glaucoma medications washout to 2 years after the surgery

07

Study locations

1 of 1 sites recruiting
  • Instituto de Olhos Ciências Médicas - Faculdade de Ciências Médicas de Minas Gerais
    Belo Horizonte, Minas Gerais 30150270, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD collected throughout the trial

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Feb 2028, 45 months after the start.

Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 45 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2025
First posted
Mar 7, 2025
StartActual
May 7, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06865235
Lead sponsor
Faculdade de Ciências Médicas de Minas Gerais
Collaborators
Hospital Evangélico de Belo Horizonte
Responsible party
DANIEL FULGENCIO DE MOURA (Head of the Glaucoma Department, Faculdade de Ciências Médicas de Minas Gerais) — Principal investigator
First posted
Mar 7, 2025
Start date
May 7, 2024
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Mar 7, 2025

Study contacts

Daniel F Moura, MD
Contact
dfmoftalmo@gmail.com
+5531991055860

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion